All Stories

  1. SGLT2 inhibition to target kidney aging
  2. Hypoglycemia in patients with end-stage kidney disease
  3. SA-β-Gal in Kidney Tubules as a Predictor of Renal Outcome in Patients with Chronic Kidney Disease
  4. Nephrological Complications in Hemoglobinopathies: SITE Good Practice
  5. Sa-β-Gal in Kidney Tubules as a Predictor of Renal Outcome in Patients with Chronic Kidney Disease
  6. The Contribution of Muscle Innate Immunity to Uremic Cachexia
  7. Nutritional and Dietary Management of Chronic Kidney Disease under Conservative and Preservative Kidney Care without Dialysis
  8. A Toll‐like receptor‐4/NLRP3 inflammasome pathway promotes inflammation in skeletal muscle of chronic kidney disease patients
  9. Homocysteine exchange across skeletal muscle in patients with chronic kidney disease
  10. Role of Uric Acid in Vascular Remodeling: Cytoskeleton Changes and Migration in VSMCs
  11. Treatment of Chronic Kidney Disease: Moving Forward
  12. Muscle atrophy in CKD: A historical perspective of advancements in its understanding.
  13. SIRPα Mediates IGF1 Receptor in Cardiomyopathy-Induced by Chronic Kidney Disease
  14. Accessing global kidney nutrition care
  15. Secondary Membranous Nephropathy Due to Benign Tumors in 2 Young Women: A Case Report
  16. Renal Ischemia/Reperfusion Early Induces Myostatin and PCSK9 Expression in Rat Kidneys and HK-2 Cells
  17. A Changing Perspective for Treatment of Chronic Kidney Disease
  18. Myostatin/Activin-A Signaling in the Vessel Wall and Vascular Calcification
  19. A Comparative Analysis of Nutritional Assessment Using Global Leadership Initiative on Malnutrition Versus Subjective Global Assessment and Malnutrition Inflammation Score in Maintenance Hemodialysis Patients
  20. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease
  21. Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD
  22. Post-transplant de novo non donor-specific HLA antibodies are not associated with poor graft outcome in non-sensitized pediatric recipients of kidney transplantation
  23. Effects of Different Dialysis Strategies on Inflammatory Cytokine Profile in Maintenance Hemodialysis Patients with COVID-19: A Randomized Trial
  24. Testosterone Disorders and Male Hypogonadism in Kidney Disease
  25. Avacopan for the Treatment of ANCA-Associated Vasculitis
  26. Effects of Late Conversion from Twice-Daily to Once-Daily Slow Release Tacrolimus on the Insulin Resistance Indexes in Kidney Transplant Patients
  27. Cellular Senescence Is Associated with Faster Progression of Focal Segmental Glomerulosclerosis
  28. Risk factors and action thresholds for the novel coronavirus pandemic. Insights from the Italian Society of Nephrology COVID-19 Survey
  29. Low Protein Diets and Plant-Based Low Protein Diets: Do They Meet Protein Requirements of Patients with Chronic Kidney Disease?
  30. Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis
  31. Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part 2): prospective study
  32. Ten-Year Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant: A Prospective Cohort Study
  33. Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy
  34. Increased serum uric acid levels are associated to renal arteriolopathy and predict poor outcome in IgA nephropathy
  35. Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy
  36. Myostatin in the Arterial Wall of Patients with End-Stage Renal Disease
  37. Nutritional management of kidney diseases: an unmet need in patient care
  38. Mechanisms Regulating Muscle Protein Synthesis in Chronic Kidney Disease
  39. Successful kidney transplantation after COVID‐19
  40. The International Society of Renal Nutrition and Metabolism Commentary on the National Kidney Foundation and Academy of Nutrition and Dietetics KDOQI Clinical Practice Guideline for Nutrition in Chronic Kidney Disease
  41. Fructose and Uric Acid: Major Mediators of Cardiovascular Disease Risk Starting at Pediatric Age
  42. Everolimus for BKV nephropathy in kidney transplant recipients: a prospective, controlled study.
  44. Management of COVID ‐19 in hemodialysis patients: The Genoa experience
  45. Long-term blood pressure behavior and progression to end-stage renal disease in patients with immunoglobulin A nephropathy
  46. Muscle protein turnover and low-protein diets in patients with chronic kidney disease
  47. Enhanced myostatin expression and signalling promote tubulointerstitial inflammation in diabetic nephropathy
  48. Nutritional Challenges in Pregnant Women with Renal Diseases: Relevance to Fetal Outcomes
  49. Activin/myostatin receptor signaling and vascular calcifications in chronic kidney disease: A “liaison dangereuse”?
  50. Wasting and Cachexia in Chronic Kidney Disease
  51. Two-Day ABPM-Derived Indices and Mortality in Hemodialysis Patients
  52. Signal regulatory protein alpha initiates cachexia through muscle to adipose tissue crosstalk
  55. Early interstitial macrophage infiltration with mild dysfunction is associated with subsequent kidney graft loss
  56. Neutrophil Extracellular Traps Profiles in Patients with Incident Systemic Lupus Erythematosus and Lupus Nephritis
  57. Indoxyl Sulfate Induces Renal Fibroblast Activation through a Targetable Heat Shock Protein 90-Dependent Pathway
  58. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Randomized Controlled Study
  59. Emerging role of myostatin and its inhibition in the setting of chronic kidney disease
  60. The Organ Handling of Soluble Klotho in Humans
  61. Immunohistochemical Staining of TLR4 in Human Skeletal Muscle Samples
  62. Uric acid and angiotensin II additively promote inflammation and oxidative stress in human proximal tubule cells by activation of toll‐like receptor 4
  63. Testosterone deficiency, frailty and muscle wasting in CKD: a converging paradigm?
  64. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study
  65. Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study
  66. Soluble Toll-like Receptor 4: A New Player in Subclinical Inflammation and Malnutrition in Hemodialysis Patients
  67. Nutritional treatment of advanced CKD: twenty consensus statements
  69. Effects of Low-Protein, and Supplemented Very Low–Protein Diets, on Muscle Protein Turnover in Patients With CKD
  70. The contribution of muscle, kidney, and splanchnic tissues to leucine transamination in humans
  71. Eating During Hemodialysis Treatment: A Consensus Statement From the International Society of Renal Nutrition and Metabolism
  72. Toll-like receptor-4 signaling mediates inflammation and tissue injury in diabetic nephropathy
  73. The nuclear phosphatase SCP4 regulates FoxO transcription factors during muscle wasting in chronic kidney disease
  74. Myostatin mediates abdominal aortic atherosclerosis progression by inducing vascular smooth muscle cell dysfunction and monocyte recruitment
  75. Glutamine Transport and Metabolism in Cancer
  76. Glutamine Supplementation in Critical Illness
  77. Interorgan handling of fibroblast growth factor-23 in humans
  78. Modulation of Myostatin/Hepatocyte Growth Factor Balance by Different Hemodialysis Modalities
  79. De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients
  80. Toll-like receptor 4 signalling mediates inflammation in skeletal muscle of patients with chronic kidney disease
  81. Kidney Intragraft Homing ofDe NovoDonor-Specific HLA Antibodies Is an Essential Step of Antibody-Mediated Damage but NotPer SePredictive of Graft Loss
  82. Low-protein diets for chronic kidney disease patients: the Italian experience
  83. Studying Muscle Protein Turnover in CKD
  84. Peripheral artery disease and blood pressure profile abnormalities in hemodialysis patients
  85. Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients
  86. Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response
  87. Insulin sensitivity of muscle protein metabolism is altered in patients with chronic kidney disease and metabolic acidosis
  88. Gene expression in highly sensitized dialysis patients waiting for a kidney transplant: A real-time PCR analysis
  89. Regression of asymptomatic cardiomyopathy and clinical outcome of renal transplant recipients: a long-term prospective cohort study
  90. Uric Acid Promotes Apoptosis in Human Proximal Tubule Cells by Oxidative Stress and the Activation of NADPH Oxidase NOX 4
  91. Enhanced glomerular Toll-like receptor 4 expression and signaling in patients with type 2 diabetic nephropathy and microalbuminuria
  92. Effect of protein-energy wasting (PEW) on muscle protein metabolism and oxygen consumption in patients with end-stage renal disease (ESRD)
  93. Effects of peritoneal dialysis on protein metabolism
  94. Stat3 Activation Links a C/EBPδ to Myostatin Pathway to Stimulate Loss of Muscle Mass
  95. Risk factors for kidney diseases and awareness of blood pressure and proteinuria in general population and in high school students: Italian report for World Kidney Days 2012-2013
  96. 1,25-Dihydroxy vitamin D and coronary microvascular function
  97. PosttransplantDe NovoDonor-Specific HLA Antibodies Identify Pediatric Kidney Recipients at Risk for Late Antibody-Mediated Rejection
  98. Lysine triggers apoptosis through a NADPH oxidase-dependent mechanism in human renal tubular cells
  99. Awareness of kidney diseases in general population and in high school students. Italian report for World Kidney Days 2010-2011
  100. Effect of kidney failure and hemodialysis on protein and amino acid metabolism
  101. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up
  102. Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens
  103. Protein-Energy Wasting and Mortality in Chronic Kidney Disease
  104. Evaluation of Metabolic Acidosis in Patients With a Kidney Graft: Comparison of the Bicarbonate-Based and Strong Ion–Based Methods
  105. Apoptosis and myostatin mRNA are upregulated in the skeletal muscle of patients with chronic kidney disease
  106. The human kidney as a regulator of body cytokine homeostasis
  107. Amino Acid Biosynthesis
  108. Pregnancy and Progression of IgA Nephropathy: Results of an Italian Multicenter Study
  109. Amino acid and protein metabolism in the human kidney and in patients with chronic kidney disease
  110. Effects of Chronic Metabolic Acidosis on Splanchnic Protein Turnover and Oxygen Consumption in Human Beings
  111. Androgen-mediated apoptosis of kidney tubule cells: Role of c-Jun amino terminal kinase
  112. The kidney is the major site of S-adenosylhomocysteine disposal in humans
  113. Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody—Associated Vasculitis
  114. Mechanisms of renal ammonia production and protein turnover
  115. Accelerated senescence in the kidneys of patients with type 2 diabetic nephropathy
  116. Effects of uremia and inflammation on growth hormone resistance in patients with chronic kidney diseases
  117. Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patients
  118. Response to ‘Renal microvascular and tubular injuries in type II diabetic nephropathy’
  119. In Reply
  120. Apoptosis in the kidneys of patients with type II diabetic nephropathy
  121. Efficacy and Safety of a Very-Low-Protein Diet When Postponing Dialysis in the Elderly: A Prospective Randomized Multicenter Controlled Study
  122. Current structure and organization for renal patient assistance in Italy
  123. Kidney and splanchnic handling of Interleukin-6 in humans
  124. Peripheral tissue release of interleukin-6 in patients with chronic kidney diseases: Effects of end-stage renal disease and microinflammatory state
  125. Causes of Hyperhomocysteinemia in Patients With Chronic Kidney Diseases
  126. Effects of Insulin on Methionine and Homocysteine Kinetics in Type 2 Diabetes With Nephropathy
  127. Insulin in methionine and homocysteine kinetics in healthy humans: plasma vs. intracellular models
  128. Central role of PKCδ in glycoxidation-dependent apoptosis of human neurons
  129. Leptin as a Uremic Toxin Interferes with Neutrophil Chemotaxis
  130. Kidney Protein Dynamics and Ammoniagenesis in Humans with Chronic Metabolic Acidosis
  131. Testosterone promotes apoptotic damage in human renal tubular cells
  132. Oxidative Stress Mediates Apoptotic Changes Induced by Hyperglycemia in Human Tubular Kidney Cells
  133. A novel role of protein kinase C-δ in cell signaling triggered by glutathione depletion
  134. Role of PKC-δ activity in glutathione-depleted neuroblastoma cells
  135. Interorgan exchange of aminothiols in humans
  136. Role of blood cells in leucine kinetics across the human kidney
  137. Taurine Prevents Apoptosis Induced by High Ambient Glucose in Human Tubule Renal Cells
  138. Determinants of outcome in ANCA-associated glomerulonephritis: A prospective clinico-histopathological analysis of 96 patients
  139. The metabolic conversion of phenylalanine into tyrosine in the human kidney: Does it have nutritional implications in renal patients?
  140. Apoptosis Induced by Serum Withdrawal in Human Mesangial Cells
  141. Amino Acid Biosynthesis
  142. Plasma protein synthesis in patients with low-grade nephrotic proteinuria
  143. Interorgan amino acid exchange
  144. Phenylalanine hydroxylation across the kidney in humans Rapid Communication
  145. Phenylalanine hydroxylation across the kidney in humans
  146. Randomized, double-blind, placebo-controlled study of arginine supplementation in chronic renal failure
  147. Muscle amino acid metabolism and the control of muscle protein turnover in patients with chronic renal failure
  148. Noramidopyrine (Metamizol) and acute interstitial nephritis
  149. Inter-organ Leptin Exchange in Humans
  150. Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients.
  151. Leucine Metabolism and Protein Dynamics in the Human Kidney
  152. Kidney, splanchnic, and leg protein turnover in humans. Insight from leucine and phenylalanine kinetics.
  153. Long-Term Response of Renal Function in Crescentic Membranous Glomerulonephritis after Plasma Exchange and Immunosuppressive Therapy
  154. Renal Metabolism of C-Peptide in Patients with Early Insulin-Dependent Diabetes mellitus
  155. Disposal of exogenous amino acids by muscle in patients with chronic renal failure
  156. Blood Amino Acid Levels and Erythropoietin Treatment in Hemodialysis Patients
  157. Skeletal muscle protein synthesis and degradation in patients with chronic renal failure
  158. Postanaesthetic myoglobinuric renal failure: an isolated expression of malignant hyperthermia
  159. Role of haematological, pulmonary and renal complications in the long-term prognosis of patients with lysinuric protein intolerance
  160. Erythropoietin Treatment and Amino Acid Metabolism in Hemodialysis Patients
  161. Effects of a Protein Meal on Blood Amino Acid Profile in Patients with Chronic Renal Failure
  162. Reversed-phase high-performance liquid chromatographic analysis of branched-chain keto acid hydrazone derivatives: optimization of techniques and application to branched-chain keto acid balance studies across the forearm
  163. Arteriovenous fistula of the native kidney: diagnosis by duplex Doppler ultrasound.
  164. Renal ammoniagenesis in humans with chronic potassium depletion
  165. Renal metabolism of amino acids in early insulin-dependent diabetes mellitus
  166. Effects of a new amino acid supplement on blood AA pools in patients with chronic renal failure
  167. Primary hyperoxaluria: a report of a case
  168. Acute Renal Failure Due to Acute Bilateral Renal Artery Thrombosis: Successful Surgical Revascularization after Prolonged Anuria
  169. Multiple venous sampling for catecholamine assay in the diagnosis of malignant pheochromocytoma
  170. Good Therapeutical Response of Goodpasture’s Syndrome with Severe Renal Failure
  171. Hypernatremia Associated with Severe Rhabdomyolysis
  172. Successful Treatment of Mitomycin C-Associated Hemolytic Uremic Syndrome by Plasmapheresis
  173. Splanchnic exchange of amino acids after amino acid ingestion in patients with chronic renal insufficiency
  174. Glyoxylic Acid in Ethylene Glycol Poisoning
  175. Effect of amino acid ingestion on blood amino acid profile in patients with chronic renal failure
  176. Renal Metabolism of C-Peptide in Man*
  177. Circadian monitoring of gastric juice mutagenicity
  178. Comparative effects of nonionic (iopamidol) and ionic (sodium and meglumine diatrizoate) contrast media for urography on urinary excretion of water and solutes
  179. Effects of Hemodialysis on Guanidinopropionic Acid Metabolism
  180. Leg Metabolism of Amino Acids and Ammonia in Patients with Chronic Renal Failure
  181. Renal ammoniagenesis in an early stage of metabolic acidosis in man.
  182. Brain metabolism of amino acids and ammonia in patients with chronic renal insufficiency
  183. Amino acid metabolism and the liver in renal failure
  184. Renal metabolism of amino acids and ammonia in subjects with normal renal function and in patients with chronic renal insufficiency.
  185. Study of bioassayable somatomedin on renal artery and vein
  186. Effects of Chronic Renal Insufficiency and Metabolic Acidosis on Glutamine Metabolism in Man
  187. Abnormalities in Amino Acid Metabolism in Chronic Renal Failure
  188. Abnormalities in Amino Acid Metabolism in Patients with Chronic Renal Failure
  189. Abnormalities in Amino Acid Metabolism in Patients with Chronic Renal Failure
  190. Amino Acid Imbalance in Patients with Chronic Renal Failure
  191. Determinants of the Partition of Renal Ammonia Production between Urine and Venous Blood in Man with Metabolic Acid-Base Disturbances
  192. Muscle Amino Acid and Protein Metabolism in Chronic Renal Failure
  193. Renal Ammoniagenesis in Man with Chronic Potassium Depletion
  194. Short- and Long-Term Effects of Methylprednisolone Pulses and Oral Cyclophosphamide in Renal Micropolyarteritis